Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption.

Morin, Sarah; Giannotti, Federica; Mamez, Anne-Claire; Pradier, Amandine; Masouridi-Levrat, Stavroula; Simonetta, Federico; Chalandon, Yves

Morin, Sarah; Giannotti, Federica; Mamez, Anne-Claire; Pradier, Amandine; Masouridi-Levrat, Stavroula; Simonetta, Federico; Chalandon, Yves.

Afiliación

Morin S; Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Giannotti F; Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Mamez AC; Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Pradier A; Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Masouridi-Levrat S; Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Simonetta F; Division of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Chalandon Y; Translational Research Center for Oncohematology, Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Front Oncol ; 13: 1095870, 2023.

Article en En | MEDLINE | ID: mdl-37007116

Palabras clave

HSCT = hematopoietic stem cell transplant; acute myeloid leukemia; drug toxicity and adverse effect; maintenance; sorafenib

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Observational_studies Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: Suiza

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google